Literature DB >> 8962403

Clinical pharmacokinetic study of mizoribine in renal transplantation patients.

K Sonda1, K Takahashi, K Tanabe, S Funchinoue, Y Hayasaka, H Kawaguchi, S Teraoka, H Toma, K Ota.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8962403

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  31 in total

1.  Population pharmacokinetics of mizoribine in pediatric recipients of renal transplantation.

Authors:  Kazuya Ishida; Osamu Motoyama; Seiichiro Shishido; Kazuo Tsuzuki; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2012-02-25       Impact factor: 2.801

2.  Induction therapy with low-dose intravenous cyclophosphamide, oral mizoribine, and steroids for severe lupus nephritis in children.

Authors:  Shuichiro Fujinaga; Kazunari Kaneko; Yoshiyuki Ohtomo; Hitohiko Murakami; Masaru Takada; Shunji Akashi; Mayako Hira; Yuichiro Yamashiro
Journal:  Pediatr Nephrol       Date:  2005-07-15       Impact factor: 3.714

3.  Population pharmacokinetics of mizoribine in adult recipients of renal transplantation.

Authors:  Kazuya Ishida; Masahiko Okamoto; Michio Ishibashi; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2011-07-14       Impact factor: 2.801

4.  Mizoribine-induced severe hyperglycemia in a patient with microscopic polyangiitis.

Authors:  Ryo Ishida; Kazumi Komaki; Tsuneyuki Nakanouchi; Tetsuro Kusaba
Journal:  CEN Case Rep       Date:  2013-09-26

5.  Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial.

Authors:  Kosuke Masutani; Akihiro Tsuchimoto; Tomomi Yamada; Makoto Hirakawa; Koji Mitsuiki; Ritsuko Katafuchi; Hideki Hirakata; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2016-01-13       Impact factor: 2.801

Review 6.  Mizoribine in the treatment of pediatric-onset glomerular disease.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Taddatsu Imaizumi
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

7.  The true distribution volume and bioavailability of mizoribine in children with chronic kidney disease.

Authors:  Takuhito Nagai; Osamu Uemura; Hisashi Kaneda; Katsumi Ushijima; Kazuhide Ohta; Yoshimitsu Gotoh; Kenichi Satomura; Masaki Shimizu; Mikiya Fujieda; Masashi Morooka; Takuji Yamada; Masayoshi Yamada; Naohiro Wada; Yukiya Hashimoto
Journal:  Clin Exp Nephrol       Date:  2016-11-21       Impact factor: 2.801

8.  Assessment of factors associated with mizoribine responsiveness in children with steroid-dependent nephrotic syndrome.

Authors:  Tomomi Kondoh; Yohei Ikezumi; Katsuyuki Yokoi; Yoko Nakajima; Yuji Matsumoto; Masahiro Kaneko; Hiroya Hasegawa; Takeshi Yamada; Naonori Kumagai; Tetsuya Ito; Tetsushi Yoshikawa
Journal:  Clin Exp Nephrol       Date:  2019-06-11       Impact factor: 2.801

9.  Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.

Authors:  Hiroshi Tanaka; Koji Tsugawa; Koichi Suzuki; Tohru Nakahata; Etsuro Ito
Journal:  Pediatr Nephrol       Date:  2006-05-24       Impact factor: 3.714

Review 10.  Mizoribine: a new approach in the treatment of renal disease.

Authors:  Yukihiko Kawasaki
Journal:  Clin Dev Immunol       Date:  2009-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.